X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3186) 3186
Publication (206) 206
Book Review (39) 39
Newsletter (25) 25
Book Chapter (7) 7
Magazine Article (7) 7
Newspaper Article (7) 7
Trade Publication Article (2) 2
Book / eBook (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2639) 2639
enoxaparin (1968) 1968
female (1600) 1600
male (1540) 1540
index medicus (1384) 1384
anticoagulants - administration & dosage (1204) 1204
enoxaparin - administration & dosage (1183) 1183
middle aged (1107) 1107
aged (1029) 1029
anticoagulants - therapeutic use (874) 874
adult (805) 805
prevention (791) 791
venous thromboembolism (786) 786
enoxaparin - therapeutic use (754) 754
molecular-weight heparin (749) 749
treatment outcome (693) 693
anticoagulants - adverse effects (692) 692
anticoagulants (689) 689
hematology (618) 618
thromboembolism (578) 578
enoxaparin - adverse effects (557) 557
unfractionated heparin (546) 546
surgery (533) 533
peripheral vascular disease (529) 529
risk factors (528) 528
heparin (506) 506
venous thromboembolism - prevention & control (469) 469
deep-vein thrombosis (466) 466
thrombosis (441) 441
thromboprophylaxis (440) 440
drug therapy (414) 414
pharmacology & pharmacy (410) 410
aged, 80 and over (397) 397
hemorrhage - chemically induced (385) 385
venous thrombosis - prevention & control (372) 372
cardiac & cardiovascular systems (365) 365
prophylaxis (363) 363
rivaroxaban (354) 354
drug administration schedule (348) 348
prospective studies (333) 333
administration, oral (332) 332
dosage and administration (331) 331
heparin, low-molecular-weight - administration & dosage (331) 331
fibrinolytic agents - administration & dosage (329) 329
retrospective studies (328) 328
postoperative complications - prevention & control (321) 321
dose-response relationship, drug (313) 313
medicine, general & internal (309) 309
warfarin (299) 299
time factors (293) 293
thromboembolism - prevention & control (290) 290
heparin - administration & dosage (279) 279
heparin, low-molecular-weight - therapeutic use (269) 269
factor xa inhibitors (258) 258
injections, subcutaneous (257) 257
fibrinolytic agents - therapeutic use (256) 256
abridged index medicus (250) 250
pharmacokinetics (250) 250
medicine & public health (244) 244
anticoagulation (240) 240
therapy (235) 235
double-blind (230) 230
risk (230) 230
care and treatment (228) 228
venous thrombosis (226) 226
safety (225) 225
heparin - therapeutic use (224) 224
low-molecular-weight heparin (222) 222
health aspects (221) 221
analysis (220) 220
anticoagulants - pharmacology (218) 218
animals (211) 211
research (208) 208
venous thromboembolism - etiology (208) 208
venous thrombosis - drug therapy (205) 205
double-blind method (204) 204
enoxaparin - pharmacology (201) 201
pulmonary-embolism (199) 199
adolescent (196) 196
trial (195) 195
drug therapy, combination (193) 193
risk assessment (193) 193
pulmonary embolism (192) 192
anticoagulants - pharmacokinetics (188) 188
follow-up studies (187) 187
randomized controlled trials as topic (187) 187
dabigatran (182) 182
management (177) 177
complications and side effects (176) 176
fondaparinux (174) 174
pregnancy (171) 171
heparin - adverse effects (169) 169
dabigatran etexilate (163) 163
fibrinolytic agents - adverse effects (163) 163
low molecular weight heparin (163) 163
heparin, low-molecular-weight - adverse effects (161) 161
myocardial infarction - drug therapy (159) 159
acute coronary syndromes (158) 158
mortality (157) 157
venous thrombosis - etiology (156) 156
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3042) 3042
German (51) 51
Spanish (36) 36
Russian (32) 32
French (27) 27
Italian (7) 7
Norwegian (6) 6
Chinese (4) 4
Danish (4) 4
Polish (4) 4
Ukrainian (4) 4
Japanese (3) 3
Czech (2) 2
Korean (2) 2
Portuguese (2) 2
Serbian (2) 2
Arabic (1) 1
Bulgarian (1) 1
Hungarian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet, ISSN 0140-6736, 08/2001, Volume 358, Issue 9282, pp. 605 - 613
Current fibrinolytic therapies fail to achieve optimum reperfusion in many patients. Low-molecular-weight heparins and platelet glycoprotein IIb/IIIa... 
MEDICINE, GENERAL & INTERNAL | THROMBOLYSIS | Recurrence | Humans | Middle Aged | Heparin - administration & dosage | Male | Tissue Plasminogen Activator - administration & dosage | Treatment Outcome | Chi-Square Distribution | Enoxaparin - administration & dosage | Immunoglobulin Fab Fragments - administration & dosage | Injections | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Survival Analysis | Female | Aged | Fibrinolytic Agents - administration & dosage | Drug Therapy, Combination | Dosage and administration | Thrombolytic drugs | Research | Tenecteplase | Drug therapy | Heart attack | Prevention | Evaluation | Ischemia | Enoxaparin | Reperfusion (Physiology) | Drug therapy, Combination | Heparin | Health aspects | Clinical trials | Heart attacks | Myocardial infarction | Coagulation | Hemorrhage | Bleeding | Infusion | Randomization | Reperfusion | Motivation | Blood platelets | Safety | Heparins | Anticoagulants | Stroke | Effectiveness | Complications | Mortality | Glycoprotein | Pharmacology | Patients | Trauma | Molecular chains | Studies | Fibrin | Monoclonal antibodies | Infarction | Heparin/administration & dosage | Medical and Health Sciences | Medicin och hälsovetenskap | Platelet Aggregation Inhibitors/administration & dosage | MEDICINE | Antibodies; Monoclonal/administration & dosage | Myocardial Infarction/drug therapy | Enoxaparin/administration & dosage | Tissue Plasminogen Activator/administration & dosage | Fibrinolytic Agents/administration & dosage | MEDICIN | Immunoglobulins; Fab/administration & dosage | Drug Therapy; Combination | Research Support; Non-U.S. Gov't
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 13, pp. 1211 - 1222
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 01/2009, Volume 101, Issue 1, pp. 77 - 85
Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE). Health technology assessment agencies... 
anticoagulants | thrombosis | prophylaxis | Embolism | Meta-analysis | Anticoagulants | Thrombosis | Prophylaxis | ENOXAPARIN | meta-analysis | RANDOMIZED-TRIAL | REPLACEMENT | ORTHOPEDIC-SURGERY | MOLECULAR-WEIGHT HEPARIN | THROMBOSIS PROPHYLAXIS | US HOSPITALS | PERIPHERAL VASCULAR DISEASE | THROMBOPROPHYLAXIS | HEMATOLOGY | UNFRACTIONATED HEPARIN | REGISTRY | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Arthroplasty, Replacement, Knee - adverse effects | Humans | Dabigatran | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Drug Administration Schedule | Risk Assessment | Administration, Oral | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Arthroplasty, Replacement, Hip - adverse effects | Venous Thromboembolism - etiology | Hemorrhage - chemically induced | Administration | Phase III as Topic | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Pyridines/administration & dosage/adverse effects/therapeutic use | Arthroplasty | Replacement | Oral | Clinical Trials | Kirurgi | Knee/adverse effects | Hemorrhage/chemically induced | Venous Thromboembolism/etiology/mortality/prevention & control | Hip/adverse effects | Anticoagulants/administration & dosage/adverse effects/therapeutic use | Surgery | Enoxaparin/administration & dosage/adverse effects/therapeutic use
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 04/2011, Volume 105, Issue 4, pp. 721 - 729
This trial compared the efficacy and safety of oral dabigatran, a direct thrombin inhibitor, versus subcutaneous enoxaparin for extended thromboprophylaxis in... 
Dabigatran etexilate | Oral anticoagulant | Total hip arthroplasty | Venous thromboembolism | Prophylaxis | SURGERY | DIRECT THROMBIN INHIBITOR | FONDAPARINUX | oral anticoagulant | PREVENTION | DEEP-VEIN THROMBOSIS | prophylaxis | total hip arthroplasty | KNEE REPLACEMENT | venous thromboembolism | MOLECULAR-WEIGHT HEPARIN | ETEXILATE | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Humans | Middle Aged | Male | Antithrombins - administration & dosage | Dabigatran | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Benzimidazoles - administration & dosage | Hemorrhage - etiology | Injections, Subcutaneous | Female | Venous Thrombosis - prevention & control | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Postoperative Complications | beta-Alanine - adverse effects | Double-Blind Method | Administration, Oral | Venous Thrombosis - mortality | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Venous Thrombosis - etiology | Venous Thromboembolism - etiology | Antithrombins - adverse effects | Survival Analysis | Arthroplasty, Replacement, Hip - mortality | Aged | Benzimidazoles | Venous Thrombosis | Oral | Hemorrhage | Antithrombins | Venous Thromboembolism | administration & dosage | Surgery | beta-Alanine | Administration | Anticoagulants | Subcutaneous | Enoxaparin | Arthroplasty | Replacement | prevention & control | Kirurgi | Hip | etiology | Injections | analogs & derivatives | adverse effects | mortality
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 1, pp. 9 - 19
Journal Article
Journal Article